- Login
- Register & Subscribe
- Language: EN FR DE
Tuesday 4 June 2013
The Institute of Metabolic Science in Cambridge UK is set to receive £24 million from the Wellcome Trust and the Medical Research Council to expand its work in metabolic disease and investigate the causes and consequences of obesity.
Country: United Kingdom
Monday 3 June 2013
MorphoSys AG has successfully outlicensed its first proprietary antibody, MOR103 for rheumatoid arthritis, to GlaxoSmithKline Plc in a deal potentially valued at €445.5 million. The German company is set to receive an upfront payment of €22.5 million.
Country: Germany
Monday 3 June 2013
Horizon Discovery Ltd has announced the final closing of its Series C funding round with share placements valued at £6.9 million. The total sum raised in the round is £18.2 million which will be used to advance its research tools including cell lines.
Country: United Kingdom
Monday 3 June 2013
Bharatt Chowrira, the chief executive of Addex Therapeutics Ltd since August 2011, has stepped down from his position as the company takes steps to further reduce costs and seek financial support for its allosteric modulation drug platform.
Country: Switzerland
Friday 31 May 2013
Six new medicines have been recommended for marketing in Europe by the European Medicines Agency, including a new treatment for patients with multiple myeloma, a rare and incurable cancer of the bone marrow.
Country: United Kingdom
Friday 31 May 2013
The ReNeuron Group Plc said it expects to seek final regulatory and ethical approvals in early July to start a Phase 2 study of its stem cell treatment for patients disabled by a stroke.
Country: United Kingdom
Thursday 30 May 2013
The US Food and Drug Administration has approved two new drugs from GlaxoSmithKline Plc for patients with metastatic melanoma linked to specific gene mutations. These are the third and fourth melanoma drugs to be approved since 2011.
Country: United Kingdom
Wednesday 29 May 2013
GlaxoSmithKline Plc has paid €250 million in cash for the Switzerland-based vaccine company, Okairos AG, which has developed technology applicable to both prophylactic and therapeutic vaccine products.
Country: United Kingdom
Wednesday 29 May 2013
Prosensa Holding BV of the Netherlands, which is developing an antisense oligonucleotide for Duchenne muscular dystrophy, has made a filing with the US Securities and Exchange Commission for a proposed initial public share offering.
Country: Netherlands
Wednesday 29 May 2013
Ugichem GmbH of Austria, which has developed a new antisense drug technology platform, has raised €2.25 million from public and private investors to advance preclinical drug candidates for immune-mediated inflammatory diseases.
Country: Austria
Monday June 10 2013
Monday June 10 2013
Thursday June 6 2013
Thursday June 6 2013
Thursday June 6 2013